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The quantitative analysis of VEGF using ELISA in various subtypes of grade I meningiomas reported higher VEGF contents in
meningothelial (2.38 ±0.62pg/µg protein, n = 7), transitional (1.08 ±0.21pg/µg protein, n = 13), and microcystic meningiomas
(1.98 ± 0.87pg/µg protein, n = 5) as compared with ﬁbrous ones (0.36 ± 0.09pg/µg protein, n = 5). In contrast to VEGF, no
diﬀerence in the concentrations of bFGF was detected. VEGF levels did not correlate with meningioma grade (1.47 ± 0.23pg/µg
versus 2.29 ± 0.58pg/µg for 32 and 16 grade I and II, resp), vascularisation (1.53 ± 0.41pg/µgv e r s u s1 .96 ± 0.28pg/µgf o r2 4l o w
and24highvascularisated tumours,resp),and braininvasion(2.32±0.59pg/µgv e r s us1.46±0.27pg/µgfor7and 41patients with
and without invasion, resp). The ELISA procedure is, thus, an interesting tool to ensure VEGF and bFGF levels in meningiomas
and to test putative correlations with clinical parameters. It is, thus, tempting to speculate that ELISA would also be valuable for
the quantitative analysis of other angiogenic growth factors and cytokines in intracranial tumours.
Copyright © 2006 Yves Denizot et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Meningiomas are the second most common primary in-
tracranial tumours. Meningiomas present clinically by caus-
ing focal or generalised seizure disorders, focal neurologi-
cal deﬁcits, or neuropsychological decline [1]. Angiogenesis
consists of the sprouting of capillaries from pre-existing ves-
sels [2]. Angiogenesis is mediated by a number of diﬀerent
growth factor and is vital for tumour growth. Vascular en-
dothelial growth factor (VEGF) and basic ﬁbroblast growth
factor (bFGF) are two potent angiogenic growth factors that
stimulated vascular endothelial cell proliferation and are in-
volved in the neoplastic angiogenesis of several types of tu-
mours including meningiomas [3–5]. Authors usually inves-
tigated VEGF and bFGF protein expressions using immuno-
histochemistry or western blotting and VEGF and bFGF
transcripts using reverse transcriptase polymerase chain re-
action. However, several studies have reported that enzyme-
linked immunosorbent assay (ELISA) is an eﬃc i e n tt o o lt o
evaluate tissue levels of these two angiogenic growth factors
[6–8]. In the present study we performed quantitative anal-
ysis of VEGF and bFGF in meningiomas in order to test if
this technical approach was also suitable for intracranial tu-
mours.
The procedure of the present study followed the rules
edited by the French National Ethics. Forty eight patients
who underwent surgery for intracranial meningiomas were
investigated. The presence or absence of a brain edema was
assessed in 36 cases. Tumours were classiﬁed according to
the WHO criteria [9]. There were 32 grade I meningiomas
including 13 transitional (2 men, 11 women, mean age 59
years), 7 meningothelial (1 man, 6 women, mean age 59
years), 5 microcystic (1 man, 4 women, mean age 51 years),
5 ﬁbroblastic (5 women, mean age 58), 1 angiomatous (1
woman, age 78 years), and 1 psammomatous (1 woman, age
27 years). Twelve tumours were grade II meningiomas: 10
atypical (5 men, 7 women, mean age 58 years) and 2 chor-
doid meningiomas (2 women, mean age 52 years). Four tu-
mours were classiﬁed as anaplastic grade III meningiomas
(4 men, mean age 51 years). The presence or the absence
of brain invasion was determined. The intensity of the neo-
vascularisation and of the chronic inﬂammatory response
in the tumours was semiquantitatively assessed. Inﬂamma-
tory inﬁltrates were usually mild and mainly composed of
lymphocytes associated with some plasmocytes. In 3 cases,
a dense lymphocytic inﬁltration was found. Tumour tis-
sues were obtained during the surgical procedure and were
frozen at −80◦C until used. Tissue samples were homoge-
nized in potassium phosphate buﬀer and VEGF and bFGF
contents were evaluated by speciﬁc ELISA assays (DuoSet,2 Mediators of Inﬂammation
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Figure 1: VEGF and bFGF contents in various subtypes of grade
I meningiomas VEGF (upper panel) and bFGF (lower panel) con-
tents were determined by ELISA. Results (in pg/µg of protein) are
reported as means ± SEM. n denotes the number of patients.
For transitional meningiomas: VEGF range [0.25–9.85] and bFGF
range [67.4–576.9]; for microcystic meningiomas: VEGF range
[0.71–5.29] and bFGF range [164.3–520.0]; for meningothelial
meningiomas: VEGF range [0.87–4.98] and bFGF range [183.6–
573.7]; for ﬁbroblastic meningiomas: VEGF range [0.10–1.69] and
bFGF range [142.1–377.3]. ∗P<. 04 and ∗∗P<. 01 as compared
with ﬁbroblastic meningiomas. Statistical analysis was performed
using the Mann-Whitney U test.
R&D Systems Europe) according to the manufacture’s rec-
ommendations [7, 8]. The detection limits for VEGF and
bFGF were 10pg/mL and 30pg/mL, respectively. All samples
were assayed in duplicate. Samples were diluted by 1/2 and
1/20 for determination of VEGF and bFGF, respectively. Pro-
teinemia was determined by the BCA protein assay reagent
(Pierce, Rockford, Ill). Results in picograms (pg) VEGF and
bFGF per micrograms (µg) of proteins are reported as means
± SEM.
VEGF and bFGF proteins were detectable in all menin-
g i o m as a m p l e s .A ss h o w ni nFigure 1 (upper panel), among
diﬀerent subtypes of grade I meningiomas, VEGF con-
tents were signiﬁcantly elevated in transitional meningiomas
(1.08 ± 0.21pg/µg protein, n = 13), microcystic menin-
giomas (1.98 ± 0.87pg/µg protein, n = 5), and meningothe-
lial meningiomas (2.38 ± 0.62pg/µg protein, n = 7) than in
ﬁbroblastic ones (0.36 ± 0.09pg/µg protein, n = 5). In con-
trast to VEGF contents, no diﬀerences were found for bFGF
contents (Figure 1, lower panel). As shown in Table 1,n o n e
of these two potent angiogenic growth factors showed any
Table 1: VEGF and bFGF values in meningiomas. VEGF and bFGF
levels are expressed as pg per µg of protein. Results are reported
as means ± SEM. n denotes the number of samples in each group
[1]. Four or more mitoses per 10 high power ﬁelds [2]. Less than
4 mitoses per 10 high power ﬁelds. No statistical diﬀerences were
observed between groups (Mann-Whitney U test).
VEGF bFGF
Grade I (n = 32) 1.47 ±0.23 341.0 ±22.9
Grade II-III (n = 16) 2.29 ±0.58 364.3 ±38.8
With necrosis (n = 9) 2.28 ±0.53 299.7 ±51.1
Without necrosis (n = 39) 1.62 ±0.28 360.1 ±0.25
With brain invasion (n = 7) 2.32 ±0.59 364.8 ±61.6
Without brain invasion (n = 41) 1.46 ±0.27 346.0 ±21.0
With edema (n = 29) 0.88 ±0.26 357.8 ±23.0
Without edema (n = 7) 1.61 ±0.21 451.1 ±54.8
High mitotic index [1]( n = 8) 1.53 ±0.38 383.7 ±66.2
Low mitotic index [2]( n = 40) 1.78 ±0.29 349.4 ±20.2
Low vascularisation (n = 24) 1.53 ±0.41 333.1 ±26.5
High vascularisation (n = 24) 1.96 ±0.28 363.2 ±29.4
Mild inﬁltrate (n = 45) 1.76 ±0.26 344.9 ±20.5
Dense inﬁltrate (n = 3) 1.49 ±0.72 407.1 ±80.6
association in relation to tumour grade, the presence of in-
ﬂammatory inﬁltrated cells, associated necrosis, edema, mi-
tosis, brain invasion, or vascularisation (Table 1).
The present study highlights that the ELISA method is a
valuable method for the quantitative analysis of bFGF and
VEGF contents in human meningiomas as previously re-
p o r t e df o ro t h e rh u m a nt u m o u r s[ 6–8]. Thus, VEGF and
bFGF proteins were detectable in all meningioma samples.
These results are in agreement with the presence of VEGF
and bFGF mRNA transcripts in meningiomas [3, 4]. The
quantitative analysis of VEGF levels in various subtypes
of grade I meningiomas highlighted diﬀerences for their
VEGF contents; ﬁbroblastic meningiomas exhibiting the
lower VEGF contents. The present results conﬁrm a previ-
ous study reporting higher VEGF contents in meningothelial
meningiomas as compared with ﬁbrous ones [10]. We found
no correlation between tumour VEGF content and menin-
gioma grade, vascularisation, and brain invasion. Taken al-
together these results suggest that VEGF could serve other
functions than sole angiogenesis in meningiomas. For exam-
ple, an autocrine VEGF stimulation of tumour cells would
be suggested explaining diﬀerences of VEGF contents be-
tween subtypes of meningiomas. Conﬁrming a previous
study, [10] bFGF contents were not diﬀerent in subtypes of
grade I meningiomas and had no correlation with menin-
giomagrade,vascularisationandbraininvasioncastingsome
doubts concerning the role of this growth factor in menin-
gioma angiogenesis. These results conﬁrm those of Samoto
et al [4] showing no correlation between meningioma vascu-
larity and bFGF transcripts. In conclusion, results obtained
with the ELISA procedure corroborate those obtained by
other investigators using other methods (such as immuno-
histochemical staining, in situ hybridization or western blot-
ting) [5, 11]. It is, thus, tempting to speculate that the ELISAYves Denizot et al 3
method would also be valuable for the quantitative analysis
of other angiogenic growth factors and cytokines in intracra-
nial tumours.
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